ArticleCancer medicine2022

Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for MSI-H/dMMR rectal cancer: A prospective, multicenter, phase Ib study.

Xiaofen Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.